Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adrianus C M Boon

Showing results (81-90 of 110) with videos related to

Pageof 11
Sort By:
Biorxiv : the Preprint Server for Biology|June 5, 2026
Antigenic characterization of SARS-CoV-2 variants BA.3.2.1 and BA.3.2.2 in three animal modelsSamuel A Turner, Joey Olivier, Madison L Ellis, et al.
Nature Communications|July 4, 2023
An immunostimulatory glycolipid that blocks SARS-CoV-2, RSV, and influenza infections in vivoMoriya Tsuji, Manoj S Nair, Kazuya Masuda, et al.
Nature Communications|July 10, 2023
Real-time environmental surveillance of SARS-CoV-2 aerosolsJoseph V Puthussery, Dishit P Ghumra, Kevin R McBrearty, et al.
ACS Sensors|July 27, 2023
Rapid Direct Detection of SARS-CoV-2 Aerosols in Exhaled Breath at the Point of CareDishit P Ghumra, Nishit Shetty, Kevin R McBrearty, et al.
Biorxiv : the Preprint Server for Biology|January 5, 2021
Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions and monocytes for optimal therapeutic protectionEmma S Winkler, Pavlo Gilchuk, Jinsheng Yu, et al.
Cell|March 10, 2021
Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protectionEmma S Winkler, Pavlo Gilchuk, Jinsheng Yu, et al.
Medrxiv : the Preprint Server for Health Sciences|June 9, 2020
Targeted Immunosuppression Distinguishes COVID-19 from Influenza in Moderate and Severe DiseasePhilip A Mudd, Jeremy Chase Crawford, Jackson S Turner, et al.
Science Advances|November 14, 2020
Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine stormPhilip A Mudd, Jeremy Chase Crawford, Jackson S Turner, et al.
Mbio|September 14, 2021
Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian HamstersWen Su, Sin Fun Sia, Aaron J Schmitz, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 12, 2025
SARS-CoV-2 nsp15 enhances viral virulence by subverting host antiviral defensesAllen Caobi, Chia-Ming Su, Christian M Beusch, et al.
Pageof 11

Showing results (81-90 of 110) with videos related to

Sort By:
Pageof 11
Biorxiv : the Preprint Server for Biology|June 5, 2026
Antigenic characterization of SARS-CoV-2 variants BA.3.2.1 and BA.3.2.2 in three animal modelsSamuel A Turner, Joey Olivier, Madison L Ellis, et al.
Nature Communications|July 4, 2023
An immunostimulatory glycolipid that blocks SARS-CoV-2, RSV, and influenza infections in vivoMoriya Tsuji, Manoj S Nair, Kazuya Masuda, et al.
Nature Communications|July 10, 2023
Real-time environmental surveillance of SARS-CoV-2 aerosolsJoseph V Puthussery, Dishit P Ghumra, Kevin R McBrearty, et al.
ACS Sensors|July 27, 2023
Rapid Direct Detection of SARS-CoV-2 Aerosols in Exhaled Breath at the Point of CareDishit P Ghumra, Nishit Shetty, Kevin R McBrearty, et al.
Biorxiv : the Preprint Server for Biology|January 5, 2021
Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions and monocytes for optimal therapeutic protectionEmma S Winkler, Pavlo Gilchuk, Jinsheng Yu, et al.
Cell|March 10, 2021
Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protectionEmma S Winkler, Pavlo Gilchuk, Jinsheng Yu, et al.
Medrxiv : the Preprint Server for Health Sciences|June 9, 2020
Targeted Immunosuppression Distinguishes COVID-19 from Influenza in Moderate and Severe DiseasePhilip A Mudd, Jeremy Chase Crawford, Jackson S Turner, et al.
Science Advances|November 14, 2020
Distinct inflammatory profiles distinguish COVID-19 from influenza with limited contributions from cytokine stormPhilip A Mudd, Jeremy Chase Crawford, Jackson S Turner, et al.
Mbio|September 14, 2021
Neutralizing Monoclonal Antibodies That Target the Spike Receptor Binding Domain Confer Fc Receptor-Independent Protection against SARS-CoV-2 Infection in Syrian HamstersWen Su, Sin Fun Sia, Aaron J Schmitz, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 12, 2025
SARS-CoV-2 nsp15 enhances viral virulence by subverting host antiviral defensesAllen Caobi, Chia-Ming Su, Christian M Beusch, et al.
Pageof 11